FFO
SRPT icon

Fortitude Family Office’s Sarepta Therapeutics SRPT Stock Holding History

Fortitude Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.46K Buy
+80
New +$1.5K ﹤0.01% 2122
2025
Q3 		– Sell
-3
Closed -$51 – 2132
2025
Q2 		$51 Buy
+3
New +$128 ﹤0.01% 2015

Other funds holding SRPT

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
QFA
Quattro Financial Advisors The Woodlands, Texas $483M AUM 11.42% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MWP
Meriwether Wealth & Planning Minden, Louisiana $222M AUM 15.77% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Fortitude Family Office's SRPT Position: Q3 2026 in Review

Fortitude Family Office opened a new position in Sarepta Therapeutics (SRPT) in Q3 2026: 80 shares worth $1.46K. The stake represents ﹤0.01% of the portfolio and ranks #2122 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in SRPT as recently as Q2 2025.

Fortitude Family Office first reported a position in SRPT in Q2 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Fortitude Family Office held 80 shares of Sarepta Therapeutics worth $1.46K as of Q3 2026.
  • Sarepta Therapeutics was a new Fortitude Family Office position in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2122 holding.
  • Fortitude Family Office first reported a position in Sarepta Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.